A Randomised, Single Centre, Double-Blind, Two-Period Crossover, Glucose Clamp Trial
NCT ID: NCT00810589
Last Updated: 2008-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
2008-11-30
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It has been shown in clinical pharmacology trials that NPL insulin has an action profile comparable to NPH insulin in subjects with type 1 diabetes. , However, a direct comparison of pharmacodynamic properties of insulin detemir and NPL insulin has not been performed to date.
To get further insight into the pharmacodynamic properties of insulin detemir compared with NPL insulin, this trial has been designed to compare pharmacodynamics in general and duration of action in particular between insulin detemir and NPL insulin in subjects with type 1 diabetes.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objective is to compare the pharmacodynamic response of insulin detemir and NPL insulin with respect to duration of action in a 32-hour euglycaemic glucose clamp experiment following single dose administration in subjects with type 1 diabetes.
Secondary objectives:
The secondary objectives are:
* to additionally characterise the pharmacodynamic profiles of insulin detemir and NPL insulin in a 32-hour euglycaemic glucose clamp experiment following single dose administration in subjects with type 1 diabetes.
* to characterise the pharmacokinetic profiles of insulin detemir and NPL insulin following single dose administration in subjects with type 1 diabetes.
* to assess the safety and tolerability of insulin detemir and NPL insulin following single dose administration in subjects with type 1 diabetes.
Trial design:
This is a randomised, single centre, double-blind, two-period crossover trial. Each subject will be randomly allocated to two single dose administrations on two separate dosing visits.
Trial population:
Thirty (30) male and female subjects with type 1 diabetes \[age 18-65 years (incl.) and body mass index between 18.0 and 32.0 kg/m2 (incl.)\] will be randomised into the trial.
Assessments:
Pharmacodynamics: The glucose infusion rate and plasma glucose concentration will be measured during a euglycaemic glucose clamp running for 32 hours after dosing.
Pharmacokinetics: Serum concentrations of insulin detemir and insulin lispro will be measured frequently during the first 32 hours after dosing.
Safety: Adverse events, laboratory safety variables (haematology, biochemistry, urinalysis), physical examination, vital signs and hypoglycaemic episodes.
Trial products:
* Insulin detemir (Levemir® Novo Nordisk), 100 U/mL in 3 mL Penfill® cartridges
* Insulin lispro protamine suspension (Humalog® NPL, Eli Lilly), 100 U/mL in 3 mL cartridges
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Levemir
0,4 IE per kg bodyweight
2
Humalog NPL Insulin
0,4 IE per kg bodyweight
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levemir
0,4 IE per kg bodyweight
Humalog NPL Insulin
0,4 IE per kg bodyweight
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosed with type 1 diabetes and treated with insulin
3. Male or female subject between 18 and 65 years of age
4. Body mass index between 18.0 and 32.0 kg/m2
5. HbA1c (glycosylated haemoglobin A1c) ≤ 11%
6. Fasting C-peptide ≤ 0.05 nmol/L
7. Treatment with intensified insulin therapy or continuous subcutaneous human insulin or insulin analogue infusion (CSII)\] for at least 3 months.
Exclusion Criteria
2. Previous participation (randomised) in this trial.
3. The receipt of any investigational product within 3 months prior
4. Clinically significant abnormal haematology or biochemistry screening tests
5. Subject who is known to have hepatitis or who is a carrier of the Hepatitis B surface antigen (HBsAg) or Hepatitis C antibodies, or has a positive result to the test for HIV antibodies.
6. Supine blood pressure at screening (after 5 min in the supine position) ≥ 180 mmHg for systolic and/or ≥ 100 mmHg for diastolic. This exclusion criterion also pertains to subjects being on antihypertensives.
7. Clinically significant abnormal ECG at screening
8. Subject who has donated blood in excess of 500 mL within the 9 weeks preceding screening.
9. Significant history of alcoholism or drug/chemical abuse
10. Smoker
11. Subject with mental incapacity or language barriers
12. Surgery or trauma with significant blood loss within the 9 weeks preceding screening.
13. Subject with a history of or presence of cancer
14. History of any illness or disease that, in the opinion of the Investigator might confound the results of the trial or pose additional risk in administering the trial product to the subject.
15. Current systemic treatment with drugs that could interfere with glucose metabolism \[such as systemic corticoids and monoamine oxidase (MAO) inhibitors\] and/or pharmacokinetics.
16. Subject who has proliferative retinopathy or maculopathy and/or severe neuropathy (in particular autonomic neuropathy)
17. Any condition that would interfere with trial participation or evaluation of results, as judged by the Investigator and/or the sponsor.
18. Female of childbearing potential who is pregnant, breast-feeding or intends to become pregnant or is not using adequate contraceptive methods
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Graz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Medical University Graz, Internal Medicine, Endocrinology and Nuclear Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas R. Pieber, MD
Role: STUDY_DIRECTOR
Medical University Graz, Internal Medicine, Endocrinology and Nuclear Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University Graz
Graz, Graz, Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ENM-HS-001
Identifier Type: -
Identifier Source: org_study_id